Eric Lefkofsky, CEO and founder of Tempus AI, explains to Scottish Mortgage manager Tom Slater the huge potential in personalising cancer diagnosis and treatment at scale. Capital at risk.

It’s been a rocky few days for Tempus AI (NASDAQ:TEM). After hitting a high of $91.45, the stock plummeted to a low of $55.20. All thanks to an earnings miss and news that CEO Jim Rogers sold ...

Popular investor Cathie Wood and her Ark Invest funds took advantage of a buying opportunity on Tuesday by purchasing over 400,000 shares of Tempus AI (TEM) as the stock plummeted 15%. This move ...

Thomas Fuller / SOPA Images / LightRocket via Getty Images Tempus AI's fourth-quarter results missed estimates as its costs increased. The medical technology firm's non-GAAP operating expenses ...

Tempus AI (NASDAQ:TEM) underwent analysis by 7 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The following table encapsulates their recent ratings ...

Tempus AI (NASDAQ:TEM) delivered a very mixed Q4 2024 earnings report that saw its shares sell off about 15% after hours. The main takeaway here is that Tempus' core business is expected to grow ...

Thank you for standing by. My name is Jason and I will be a conference operator for today. At this time, I would like to welcome everyone to the Tempus fourth-quarter 2024 financial results conference ...

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today reported financial results for the ...

CHICAGO, February 24, 2025--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today reported financial ...

Tempus AI reports fourth-quarter revenue of $200.68 million, missing estimates of $203.12 million. Tempus reports a fourth-quarter adjusted loss of 18 cents per share, beating analyst estimates ...